Nov 5, 2021
|
Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021
|
Nov 4, 2021
|
Ardelyx to Pursue Formal Dispute Resolution for Tenapanor
|
Oct 29, 2021
|
Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021
|
Oct 13, 2021
|
Ardelyx Provides Corporate Update Following Type A Meeting with FDA
|
Sep 3, 2021
|
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial
|
Aug 13, 2021
|
Ardelyx Reports Second Quarter 2021 Financial Results
|
Jul 29, 2021
|
Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
Jul 19, 2021
|
Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
Jun 7, 2021
|
Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021
|
May 25, 2021
|
Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference
|